Market Research Logo

Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016

Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016’, provides in depth analysis on Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted pipeline therapeutics.

The report provides comprehensive information on the Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26)
  • The report reviews Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) pipeline Target constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Glycogen Synthase Kinase 3 Beta – Pipeline Review, H1 2016, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 4 molecules, respectively.

Furthermore, this report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Introduction
Global Markets Direct Report Coverage
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Overview
Therapeutics Development
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Products under Development by Stage of Development
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Products under Development by Therapy Area
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Products under Development by Indication
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Products under Development by Companies
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Products under Development by Universities/Institutes
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Companies Involved in Therapeutics Development
AMO Pharma Limited
Angelini Group
Celon Pharma Sp. z o.o.
DiaMedica Inc.
HitGen LTD
Jeil Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Neurim Pharmaceuticals Ltd
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Drug Profiles
CPL-202100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DM-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DM-204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-AD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JGK-263 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
manzamine A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GSK3b for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GSK3 Beta for Type 2 Diabetes, Oncology and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tideglusib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Dormant Projects
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Discontinued Products
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Featured News & Press Releases
Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia
Nov 04, 2015: DiaMedica Provides Corporate Update
Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference
Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases
Nov 17, 2014: DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
Aug 07, 2014: DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Jun 10, 2014: DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference
Feb 19, 2014: DiaMedica announces successful completion of Phase 1 program for DM199
Jan 09, 2014: DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients
Sep 30, 2013: DiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic Patients
Aug 20, 2013: DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study
Jun 24, 2013: DiaMedica Advances DM-199 Phase I/II Clinical Program For Treatment Of Type 2 Diabetes
Jun 20, 2013: Sanford Project & DiaMedica To Present Preclinical Abstract on DM-199 For Treatment Of Type 1 Diabetes At 73rd Annual ADA Conference
May 01, 2013: DiaMedica Initiates Phase I/II Clinical Trial Of DM-199 For Treatment Of Type 2 Diabetes
Apr 08, 2013: DiaMedica Receives Phase I/II Clinical Trial Regulatory Approval For DM-199 As Potential Treatment For Diabetes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by AMO Pharma Limited, H1 2016
Pipeline by Angelini Group, H1 2016
Pipeline by Celon Pharma Sp. z o.o., H1 2016
Pipeline by DiaMedica Inc., H1 2016
Pipeline by HitGen LTD, H1 2016
Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
Pipeline by Neurim Pharmaceuticals Ltd, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report